I attended a memorial service last year for a man I went to college with — a man who had once been brilliant, funny, generous, and reliably the last person to leave any party. He died at forty-one of a fentanyl overdose in the bathroom of a gas station in suburban Ohio. He had been in and out of treatment four times. He had been sober for eleven months before his final relapse. His family had done everything the system told them to do. The system had not done enough.
His story is one of over 500,000 — the estimated number of Americans who have died from opioid-related overdoses since 1999 (CDC, 2023). The opioid crisis has become the deadliest drug epidemic in American history, exceeding the combined death toll of every previous drug crisis, including the crack cocaine epidemic of the 1980s and the heroin epidemic of the 1970s. And despite billions of dollars in litigation settlements, expanded treatment funding, and aggressive supply-side interventions, overdose deaths reached an all-time high of 109,680 in 2022 before declining modestly in 2023 (Ahmad et al., 2024).
The opioid crisis is not over. But it has changed — in its pharmacology, its demographics, its geographic distribution, and its relationship to the broader landscape of American healthcare failure. Understanding where the crisis stands now requires understanding both what we have learned and what we stubbornly continue to ignore.
The three waves
Epidemiologists describe the opioid crisis in three overlapping waves, each defined by the primary substance driving overdose deaths:
Wave 1: Prescription opioids (1999-2010). The crisis began with the aggressive marketing of prescription opioid analgesics — particularly OxyContin (oxycodone), introduced by Purdue Pharma in 1996 — for chronic non-cancer pain. Purdue's marketing materials, now thoroughly documented through litigation, minimized the addictive potential of OxyContin, promoted the concept of "pseudoaddiction" (the theory that patients who appeared addicted were actually undertreated for pain), and deployed a sales force that targeted the highest-prescribing physicians in the country (Keefe, 2021).
The medical establishment, led by influential pain societies and the Joint Commission's designation of pain as "the fifth vital sign," created a clinical culture in which opioid prescribing for chronic pain became normalized and aggressive pain treatment was treated as an indicator of quality care. Prescribing volumes quadrupled between 1999 and 2010, and by 2012, enough opioid prescriptions were dispensed to provide every American adult with a bottle of pills (CDC, 2017).
Wave 2: Heroin (2010-2013). As prescription opioid availability tightened — through reformulation of OxyContin to deter misuse, the implementation of prescription drug monitoring programs, and physician education initiatives — many individuals who had developed opioid dependence through prescription exposure transitioned to heroin, which was cheaper, more readily available, and pharmacologically similar. Heroin overdose deaths tripled between 2010 and 2014.
Wave 3: Synthetic opioids (2013-present). The current and most lethal phase of the crisis is dominated by illicitly manufactured fentanyl and its analogs — synthetic opioids that are 50-100 times more potent than morphine. Fentanyl is inexpensive to produce, easy to conceal and transport, and has been increasingly mixed into virtually every category of illicit drug — heroin, cocaine, methamphetamine, counterfeit prescription pills — making overdose a risk for individuals who may not know they are consuming opioids at all. Synthetic opioid-involved overdose deaths increased approximately 22-fold between 2013 and 2022 (CDC, 2023).
What we have learned
The opioid crisis has generated an enormous body of research, litigation, and policy reform. Several lessons have emerged with particular clarity:
Addiction is a chronic brain disease, not a moral failure. The neuroscience of addiction — involving persistent changes in the brain's reward circuitry, stress systems, and prefrontal executive function — is now well-established. Repeated opioid exposure produces neuroplastic changes in the mesolimbic dopamine system that alter reward valuation, in the extended amygdala that intensify negative emotional states during withdrawal, and in the prefrontal cortex that impair decision-making and impulse control (Koob & Volkow, 2016). These changes are measurable on neuroimaging, persistent across months to years of abstinence, and fundamentally alter the brain's motivational architecture in ways that are not adequately described by the language of "choice." The characterization of addiction as a brain disease does not absolve individual responsibility, but it does explain why willpower-based approaches (telling people to "just stop") are insufficient and why evidence-based treatment is necessary.
Medication-assisted treatment works. The three FDA-approved medications for opioid use disorder — methadone, buprenorphine, and naltrexone — represent the most effective treatments available. Methadone and buprenorphine, in particular, have been shown to reduce overdose mortality by 50-70%, decrease illicit opioid use, reduce criminal activity, improve employment and social function, and decrease transmission of blood-borne infections including HIV and hepatitis C (Wakeman et al., 2020). These are not modest effect sizes — they are among the most robust treatment effects in all of medicine.
Yet medication-assisted treatment remains dramatically underutilized. Only approximately 25% of individuals with opioid use disorder receive any form of evidence-based pharmacological treatment (SAMHSA, 2022). The barriers are structural: methadone can only be dispensed through federally certified opioid treatment programs, which are unevenly distributed and carry stigma. Buprenorphine, while prescribable in office settings since 2000, was until recently subject to a waiver requirement ("X-waiver") that limited prescriber numbers and created administrative barriers. The waiver requirement was eliminated in 2023, but prescribing adoption has been slow to increase.
Naloxone saves lives. Naloxone (Narcan), an opioid antagonist that reverses overdose within minutes, has been credited with reversing over 100,000 overdoses since its widespread community distribution began in 2014 (Wheeler et al., 2015). The FDA approved over-the-counter naloxone in 2023, removing the prescription requirement and expanding access. Naloxone is not a treatment for addiction — it is a rescue medication. But in a crisis dominated by fentanyl, in which a lethal dose is measured in milligrams, naloxone access is the difference between life and death for hundreds of thousands of individuals.
Supply-side approaches alone are insufficient. The aggressive effort to reduce prescription opioid supply — which succeeded in reducing prescribing volumes by approximately 44% from the 2012 peak — did not reduce overdose deaths. Total overdose mortality continued to increase as individuals transitioned from prescription opioids to heroin and then to fentanyl. Supply reduction without concurrent expansion of treatment and harm reduction simply shifted the source of opioids from regulated pharmaceutical products to unregulated illicit markets — where the product is more dangerous, the doses are unpredictable, and the mortality risk is dramatically higher (Ciccarone, 2019).
What we have not learned
Despite the lessons above, the policy response to the opioid crisis continues to be distorted by stigma, ideology, and structural failures that have characterized American drug policy for over a century:
We continue to criminalize addiction. Approximately 1.16 million drug-related arrests occur annually in the United States, the majority for possession rather than distribution (FBI, 2022). Incarceration does not treat addiction — it interrupts treatment, removes social support, exposes individuals to additional trauma, and dramatically increases overdose risk upon release. The two-week period following release from incarceration is the highest-risk period for fatal overdose, as tolerance decreases during incarceration while the impulse to use remains (Merrall et al., 2010). Portugal decriminalized personal drug possession in 2001 and redirected resources from criminal justice to treatment and harm reduction. In the subsequent two decades, drug-related HIV infections declined by 95%, overdose deaths declined by approximately 80%, and drug use rates remained comparable to European averages (Greenwald, 2009).
We resist harm reduction. Supervised consumption sites — facilities where individuals can use pre-obtained drugs under medical supervision with access to sterile supplies, naloxone, and treatment referrals — have been operating in Europe, Canada, and Australia for decades with extensive evidence of efficacy. A systematic review found that supervised consumption sites were associated with reduced overdose mortality, reduced public injection, reduced syringe sharing, and increased treatment entry — without increasing drug use or drug-related crime in surrounding neighborhoods (Potier et al., 2014). New York City opened the first sanctioned supervised consumption sites in the United States in 2021; Rhode Island authorized them in 2022. But political opposition remains fierce, and the vast majority of American communities reject harm reduction approaches on moral grounds despite overwhelming scientific evidence.
We have not addressed the demand side. The opioid crisis emerged from — and continues to be sustained by — a landscape of economic dislocation, social isolation, untreated mental illness, intergenerational trauma, and despair that constitutes the demand for pain relief that opioids temporarily supply. The counties with the highest opioid prescribing rates in the initial wave of the crisis were disproportionately rural, economically disadvantaged, and socially disintegrated — communities where employment had declined, institutions had closed, and hopelessness had become ambient (Ruhm, 2019).
Addressing the opioid crisis without addressing the conditions that create demand for opioids is treating the symptom while ignoring the disease. And the "deaths of despair" framework proposed by Anne Case and Angus Deaton — which encompasses opioid overdose, alcohol-related liver disease, and suicide as manifestations of a single phenomenon of declining social and economic wellbeing among non-college-educated Americans — suggests that even if the opioid supply were somehow eliminated entirely, the underlying despair would find alternative expression (Case & Deaton, 2015).
The litigation settlements
The legal reckoning for the pharmaceutical industry's role in the opioid crisis has produced settlements exceeding $50 billion — the largest in the history of American civil litigation. Purdue Pharma, the manufacturer of OxyContin, agreed to a $6 billion settlement and dissolution. The "Big Three" distributors — McKesson, AmerisourceBergen, and Cardinal Health — agreed to a $21 billion settlement. Johnson & Johnson agreed to $5 billion. Teva, Allergan, Endo, and numerous other manufacturers and distributors have contributed billions more.
The disposition of these funds will determine whether the settlements produce meaningful health impact or become another chapter in the long history of litigation-driven revenue being diverted from its stated purpose. (The 1998 tobacco Master Settlement Agreement, which generated $246 billion for states, was largely diverted to general revenue rather than tobacco prevention and cessation programs — fewer than 3% of settlement funds were spent on their intended purpose in most states.) Early evidence from opioid settlement disbursements is mixed: some states and local governments are directing funds toward treatment expansion, naloxone distribution, and harm reduction. Others are using settlement funds for general budget relief, capital projects, and purposes unrelated to the opioid crisis (Christine et al., 2023).
The path forward
The opioid crisis will not end with a single policy, a single medication, or a single legal settlement. It will be addressed — slowly, imperfectly, incrementally — through a comprehensive, evidence-based approach that integrates:
Treatment expansion: eliminating barriers to medication-assisted treatment, integrating addiction treatment into primary care, expanding treatment capacity in rural and underserved areas, and treating opioid use disorder as the chronic medical condition it is rather than the moral failure it is not.
Harm reduction: scaling naloxone distribution, establishing supervised consumption sites, expanding syringe service programs, and implementing drug checking services that allow individuals to test substances for fentanyl contamination.
Prevention: addressing the social determinants that create demand for substances — economic opportunity, housing stability, mental health access, social connection, and community resilience.
Accountability: ensuring that litigation settlements are directed toward evidence-based interventions and monitored for impact, and reforming the regulatory and marketing practices that enabled pharmaceutical companies to market addictive substances with misleading safety claims.
The man I knew in college deserved better. The 500,000 Americans who have died deserved better. The millions still struggling with opioid use disorder deserve better now. The science tells us what works. What we lack, as we have lacked throughout this crisis, is the political courage to implement it.
References
- Ahmad, F. B., et al. (2024). Provisional Drug Overdose Death Counts. National Center for Health Statistics.
- Case, A., & Deaton, A. (2015). Rising morbidity and mortality in midlife among white non-Hispanic Americans. PNAS, 112(49), 15078–15083.
- CDC. (2017). Annual Surveillance Report of Drug-Related Risks and Outcomes. Centers for Disease Control and Prevention.
- CDC. (2023). Understanding the Opioid Overdose Epidemic. Centers for Disease Control and Prevention.
- Christine, P. J., et al. (2023). National opioid settlement fund allocation. JAMA Health Forum, 4(8), e232476.
- Ciccarone, D. (2019). The triple wave epidemic: Supply and demand drivers of the US opioid overdose crisis. International Journal of Drug Policy, 71, 183–188.
- FBI. (2022). Crime in the United States. Federal Bureau of Investigation.
- Greenwald, G. (2009). Drug Decriminalization in Portugal. Cato Institute.
- Keefe, P. R. (2021). Empire of Pain. Doubleday.
- Koob, G. F., & Volkow, N. D. (2016). Neurobiology of addiction: A neurocircuitry analysis. The Lancet Psychiatry, 3(8), 760–773.
- Merrall, E. L., et al. (2010). Meta-analysis of drug-related deaths soon after release from prison. Addiction, 105(9), 1545–1554.
- Potier, C., et al. (2014). Supervised injection services: What has been demonstrated? A systematic literature review. Drug and Alcohol Dependence, 145, 48–68.
- Ruhm, C. J. (2019). Drivers of the fatal drug epidemic. Journal of Health Economics, 64, 25–42.
- SAMHSA. (2022). National Survey on Drug Use and Health. Substance Abuse and Mental Health Services Administration.
- Wakeman, S. E., et al. (2020). Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Network Open, 3(2), e1920622.
- Wheeler, E., et al. (2015). Opioid overdose prevention programs providing naloxone to laypersons. Annals of Internal Medicine, 163(1), 59–68.